There were no observed differences between treatment groups regarding tumor size after debulking surgery.,There observed differences treatment tumor size debulking surgery.,G0000000|C1441672|C1705241|C0039798|C0027651|C0456389|C0439805|C0038894
"In conclusion, olaparib resulted in statistically significant and clinically relevant improvements in ORR and PFS compared with nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCAm who had received at least 2 prior lines of platinum-based chemotherapy.","In conclusion, olaparib statistically clinically relevant improvements ORR PFS compared nonplatinum chemotherapy patients platinum-sensitive relapsed ovarian cancer germline BRCAm received 2 prior lines platinum-based chemotherapy.",G0000000|C1707478|C2316164|C0038215|G0000000|C2347946|C2986411|G0000000|C0242792|C1707455|G0000000|C0013216|C0030705|C0032207|C0205336|C0205065|C0006826|C0017473|G0000000|C1514756|G0000000|C0332152|C0205132|C0032207|C0013216
"No between-group difference was found in the primary outcome measure, 30-day CCI (adjusted mean difference, −3.2; 95% CI, −11.8 to 5.3; P = .45).","No between-group difference primary outcome measure, 30-day CCI (adjusted difference, −3.2; 95% CI, −11.8 5.3; P = .45).",G0000000|C0441833|C1705241|C0205225|C1274040|C0079809|C0450371|C1861617|C0456081|C1705241|G0000000|C0450371|C0008107|G0000000|G0000000|G0000000
"In terms of secondary end points, PFS significantly favored olaparib versus chemotherapy in these heavily pretreated patients.","In terms secondary points, PFS favored olaparib versus chemotherapy heavily pretreated patients.",G0000000|C0233324|C0027627|C1552961|C0242792|C0309049|C2316164|G0000000|C0013216|G0000000|G0000000|C0030705
"In aggregate, malaria infections, spleen rates, haemoglobin concentrations, and weight for height, did not differ significantly during the study period between villages with and without ITNs, with a weighted mean difference of −2.6 P. falciparum episodes per 1,000 weeks at risk (95% Confidence Interval −7 to 1.8).","In aggregate, malaria infections, spleen rates, haemoglobin concentrations, weight height, study period villages ITNs, weighted difference −2.6 P. falciparum episodes 1,000 weeks risk (95% Confidence Interval −7 1.8).",G0000000|C0205418|C0024530|C3714514|C0037993|C0871208|C0019046|C0086045|C0005910|C0489786|C0557651|C0439531|C0562518|G0000000|C0005910|C1705241|G0000000|C0369773|G0000000|C0332189|C1442061|C0439230|C0035647|C0450371|C0237529|C1272706|G0000000|G0000000
The primary outcome included the Comprehensive Complications Index measured at 30 days after surgery.,The primary outcome included Comprehensive Complications Index measured 30 days surgery.,G0000000|C0205225|C1274040|C0332257|C1880156|C0009566|C0918012|C0444706|C0450371|C0439228|C0038894
"Despite this potential improvement in walking capacity when patients adhered to the Prehab program, no between-group differences in 30-day CCI (adjusted mean difference, −4.3; 95% CI, –14.5 to 6.0; P = .41) or in other outcome measures assessed in the trial were noted.","Despite potential improvement walking capacity patients adhered Prehab program, between-group differences 30-day CCI (adjusted difference, −4.3; 95% CI, –14.5 6.0; P = .41) outcome measures assessed trial noted.",G0000000|C3245505|C2986411|C0080331|C1516240|C0030705|C3714578|G0000000|C1709697|C0441833|C1705241|C0450371|C1861617|C0456081|C1705241|G0000000|C0450371|C0008107|G0000000|G0000000|G0000000|C1274040|C0079809|C1516048|C0008976|C1316572
"In conclusion, treatment with 10 mg nicotine inhaler or 4 mg nicotine chewing gum resulted in a significantly higher abstinence rate than placebo.","In conclusion, treatment 10 nicotine inhaler 4 nicotine chewing gum abstinence rate placebo.",G0000000|C1707478|C0039798|C0450371|C0028040|C0021461|G0000000|C0028040|C0024888|C0017562|C3843422|C0871208|C0032042
"The frequencies of sepsis, IVH, need for supplemental oxygen, need for mechanical ventilation and use of the specified medications did not differ significantly among the groups, nor did early specified clinical diagnoses during the first 4 days after infusion (Table 2).","The frequencies sepsis, IVH, supplemental oxygen, mechanical ventilation medications groups, clinical diagnoses 4 days infusion (Table 2).",G0000000|C0439603|C0036690|G0000000|C2348609|C0030054|C0443254|C0035203|C0013227|C0441833|C0205210|C0011900|G0000000|C0439228|C0574032|C0039224|G0000000
The NIHSS index for neurologic deficit evaluation was used as the primary outcome measurements.,The NIHSS neurologic deficit evaluation primary outcome measurements.,G0000000|C3476804|C0205494|C0162429|C0220825|C0205225|C1274040|C0242485
"The swallowing function was evaluated at baseline and 3, 6, and 12 weeks after baseline.","The swallowing function evaluated baseline 3, 6, 12 weeks baseline.",G0000000|C0011167|C0031843|C0220825|C0168634|G0000000|G0000000|C0450371|C0439230|C0168634
"The DASH upper-extremity score decreased by 6.7 points (33% decrease) in women randomly assigned to exercise at 12 months, compared with a 1.3-point increase (12% increase) in those receiving usual care (difference, 8.0; 95% CI, 3.1 to 12.9; P = .002).","The DASH upper-extremity score decreased 6.7 (33% decrease) women randomly assigned exercise 12 months, compared 1.3-point increase (12% increase) receiving usual care (difference, 8.0; 95% CI, 3.1 12.9; P = .002).",G0000000|C2827624|C1140618|C0449820|C0205216|G0000000|C0450371|C0392756|C0043210|G0000000|C1516050|C0015259|C0450371|C0439231|C1707455|C1552961|C0442805|C0450371|C0442805|C1514756|C3538928|C1947933|C1705241|G0000000|C0450371|C0008107|G0000000|C0450371|C0369773|G0000000|C1442061
Adverse events (AEs) were assessed by using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.,Adverse events (AEs) assessed NCI Common Terminology Criteria Adverse Events (CTCAE) version 3.0.,G0000000|C0441471|C1412268|C1516048|C1513882|C0205214|C0028275|C0243161|G0000000|C0441471|C1516728|C0333052|G0000000
"We did not find statistical significance between serum Ca, P, Alb, BUN and Hematocrit, P>0.05.","We statistical significance serum Ca, P, Alb, BUN Hematocrit, P>0.05.",G0000000|C0038215|C0237881|C0229671|C3887642|C0369773|G0000000|G0000000|C0018935|C0369773
These findings demonstrate among preterm infants of 23–29 weeks gestation that a single IV dose of 60 mg/kg or 120 mg/kg inositol given over 20 minutes results in an initial dose proportional increase in serum concentrations that persists between 24 to 36 h.,These findings demonstrate preterm infants 23–29 weeks gestation single IV dose 60 mg/kg 120 mg/kg inositol 20 minutes initial dose proportional increase serum concentrations persists 24 36 h.,G0000000|C2607943|G0000000|C0151526|C0021270|G0000000|C0439230|C0032961|C0037179|C0022326|C0178602|C0450371|C0439272|C1442061|C0439272|C0021547|C0450371|C0439232|C0205265|C0178602|C0205351|C0442805|C0229671|C0086045|G0000000|C0450371|C0450371|C0033727
Our study demonstrated that repeated four-monthly anthelminthic treatments with albendazole were successful in reducing prevalence and intensity of A. lumbricoides infections.,Our study demonstrated repeated four-monthly anthelminthic treatments albendazole successful reducing prevalence intensity A. lumbricoides infections.,G0000000|C0557651|G0000000|C0205341|C0205450|C0003158|C0087111|C0001911|C0597535|C0392756|C0033105|C0522510|G0000000|G0000000|C3714514
"Over 12 months, worst joint pain scores decreased by 1.6 points (29% decrease) in women randomly assigned to exercise, versus a 0.2-point increase (3% increase) in women randomly assigned to usual care (difference, 1.8; 95% CI, 0.9 to 2.6; P < .001).","Over 12 months, worst joint pain scores decreased 1.6 (29% decrease) women randomly assigned exercise, versus 0.2-point increase (3% increase) women randomly assigned usual care (difference, 1.8; 95% CI, 0.9 2.6; P < .001).",C0205136|C0450371|C0439231|C1522166|C0022417|C0030193|C0449820|C0205216|G0000000|C0450371|C0392756|C0043210|G0000000|C1516050|C0015259|G0000000|C1552961|C0442805|G0000000|C0442805|C0043210|G0000000|C1516050|C3538928|C1947933|C1705241|G0000000|C0450371|C0008107|G0000000|G0000000|C0369773|G0000000|C1442061
The primary endpoint was the invasive cancer detection rate.,The primary endpoint invasive cancer detection rate.,G0000000|C0205225|C2349179|C0205281|C0006826|C1511790|C0871208
"They did not find any significant difference in growth parameters, age at full enteral feeding or length of hospital stay between the intervention group and the control group.","They difference growth parameters, age enteral feeding length hospital stay intervention control group.",G0000000|C1705241|C0018270|C0449381|C0001779|C1304890|C0204695|C1444754|C0019994|G0000000|C0886296|C0243148|C0441833
"And as a result, early NMES applied patients showed a significant improvement in their swallowing function at 3, 6, and 12 weeks after onset of stroke compared with the TDT only group.","And result, NMES applied patients improvement swallowing function 3, 6, 12 weeks onset stroke compared TDT group.",G0000000|C1274040|C2985393|C4048755|C0030705|C2986411|C0011167|C0031843|G0000000|G0000000|C0450371|C0439230|C0206132|C0038454|C1707455|C3887634|C0441833
"Pulmonary function tests, including forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1), were performed before and after each treatment cycle using a body plethysmograph (Viasys Healthcare GmbH, Germany).","Pulmonary function tests, including forced vital capacity (FVC) forced expiratory volume 1 (FEV1), performed treatment cycle body plethysmograph (Viasys Healthcare GmbH, Germany).",C0024109|C0031843|C0022885|C0332257|C0441722|C0442732|C1516240|C3714541|C0441722|C0231800|C0449468|G0000000|G0000000|C0884358|C0039798|C1511572|C0242821|C0182319|G0000000|C0086388|G0000000|C0017480
"Among premature infants younger than 28 weeks’ gestational age, treatment with myo-inositol for up to 10 weeks did not reduce the risk of type 1 ROP or death vs placebo.","Among premature infants 28 weeks’ gestational age, treatment myo-inositol 10 weeks reduce risk type 1 ROP death placebo.",G0000000|C0151526|C0021270|C0450371|G0000000|C0439671|C0001779|C0039798|C0021547|C0450371|C0439230|G0000000|C0035647|C0332307|G0000000|C0035344|C0011065|C0032042
"The results showed a clear association between green tea consumption and lung cancer risk in current and ever smokers who drank less green tea (<1 cup per day and never drank green tea, P for trend <0.0001).","The association green tea consumption lung cancer risk current smokers drank green tea (<1 cup day drank green tea, P trend <0.0001).",G0000000|C0004083|C0332583|C0039400|C0009830|C0024109|C0006826|C0035647|C0521116|C0337664|C0452428|C0332583|C0039400|G0000000|C1533124|C0332173|C0452428|C0332583|C0039400|C0369773|C1521798|G0000000
"Finally, while our evidence shows that the intervention had no impact on nutritional indicators, cognitive abilities, or school performance in this lightly infected population, the impact on populations with moderate-to-high levels of infection intensity is an area for further investigation.","Finally, evidence intervention impact nutritional indicators, cognitive abilities, school performance lightly infected population, impact populations moderate-to-high levels infection intensity investigation.",G0000000|C3887511|C0886296|C1825598|C1521739|C0021212|C1516691|C0085732|C0036375|C0597198|C1881376|C0439663|C0032659|C1825598|C0032659|C0205081|C0441889|C0009450|C0522510|C0220825
Worm infection and weight-for-age (WAZ) and height-for-age (HAZ) data were collected and specified in this analysis as secondary outcomes.,Worm infection weight-for-age (WAZ) height-for-age (HAZ) data collected analysis secondary outcomes.,C0018889|C0009450|C0005910|G0000000|C0489786|G0000000|C1511726|C1516695|C0002778|C0027627|C1274040
"Secondary outcomes included sensitivity, specificity, the additional-imaging-recommendation-rate, and positive predictive value (PPV) of biopsy, using invasive cancer and DCIS to define a positive reference standard.","Secondary outcomes included sensitivity, specificity, additional-imaging-recommendation-rate, positive predictive (PPV) biopsy, invasive cancer DCIS define positive reference standard.",C0027627|C1274040|C0332257|C0020517|C0037791|C1524062|C0439178|C0681890|C1514243|C0005558|C0205281|C0006826|C0007124|G0000000|C0439178|C1514811|C1442989
The primary end point was RFS; secondary end points were OS and immunologic response.,The primary RFS; secondary OS immunologic response.,G0000000|C0205225|C0341703|C0027627|C0229090|C0152036|C0871261
The primary outcome measure is thirty-day abstinence at six months; a secondary outcome is biochemically validated smoking status.,The primary outcome measure thirty-day abstinence months; secondary outcome biochemically validated smoking status.,G0000000|C0205225|C1274040|C0079809|C1710392|C3843422|C0439231|C0027627|C1274040|G0000000|G0000000|C0037369|C0449438
Secondary outcomes analyzed were infection intensity (fecal egg counts) and anemia prevalence.,Secondary outcomes analyzed infection intensity (fecal egg counts) anemia prevalence.,C0027627|C1274040|C0936012|C0009450|C0522510|C0015733|C0013710|C0439157|C0002871|C0033105
"Outcomes: Study feasibility (recruitment rate, compliance with data collection) and clinical data to inform the design of a definitive randomised controlled trial (blood pressure monitoring, National Institute of Health Stroke Scale, Barthel ADL Index, Modified Rankin Scale, renal function).","Outcomes: Study feasibility (recruitment rate, compliance data collection) clinical data inform design definitive randomised controlled trial (blood pressure monitoring, National Institute Health Stroke Scale, Barthel ADL Index, Modified Rankin Scale, renal function).",C1274040|C0557651|G0000000|C2949735|C0871208|C0009563|C1511726|C1516698|C0205210|C1511726|C0537670|C1707689|C0443196|G0000000|C2587213|C0008976|C0005767|C0033095|C0150369|C3245503|C0021622|C0018684|C0038454|C0175659|G0000000|C0001288|C0918012|C0392747|G0000000|C0175659|C0022646|C0031843
The nicotine patch significantly improves short-term quit rates in inner-city African Americans who are interested in trying to quit smoking.,The nicotine patch improves short-term quit rates inner-city African Americans quit smoking.,G0000000|C0028040|C0332461|C0184511|C0443303|C0748223|C0871208|C0557849|C0027567|C0596070|C0748223|C0037369
At the end of the study women in the NRT and CBT group did have a significantly higher quit rate.,At study women NRT CBT quit rate.,G0000000|C0557651|C0043210|C1278444|C0009244|C0748223|C0871208
This resulted in a significantly decreased number of recurrences of acute otitis media in the treated children compared with those given placebo.,This decreased recurrences acute otitis media treated children compared placebo.,G0000000|C0205216|C0034897|C0205178|C0029877|C0009458|C1522326|C0008059|C1707455|C0032042
Similar results also showed a significant combined effect of cumulative smoking dose and IGF2 and IGFBP3 genotypes.,Similar combined cumulative smoking dose IGF2 IGFBP3 genotypes.,C2348205|C0205195|C1511559|C0037369|C0178602|G0000000|G0000000|C0017431
"The main outcome measure was self-report of cessation since last visit, confirmed by exhaled carbon monoxide.","The main outcome measure self-report cessation visit, confirmed exhaled carbon monoxide.",G0000000|C0205225|C1274040|C0079809|C0681906|C1880019|C0545082|C0521093|C0231800|C0007009|G0000000
Secondary outcome measures were also not different between groups.,Secondary outcome measures groups.,C0027627|C1274040|C0079809|C0441833
"When compared with the control group, the functional dysphagia scale, vallecular residue, and penetration-aspiration scale were significantly improved in the experimental group.","When compared control group, functional dysphagia scale, vallecular residue, penetration-aspiration scale improved experimental group.",G0000000|C1707455|C0243148|C0441833|C0205245|C0011168|C0175659|C0227157|C1709915|C0205321|C0175659|C0184511|C1517586|C0441833
"The primary endpoint was the rate of invasive cancer detection by each modality on the study baseline-screening at the participant level, defined as the fraction of participants in whom an invasive cancer was detected by the modality at the site of the imaging abnormality as verified by pathology (core biopsy or surgical excision).","The primary endpoint rate invasive cancer detection modality study baseline-screening participant level, defined fraction participants invasive cancer detected modality site imaging abnormality verified pathology (core biopsy surgical excision).",G0000000|C0205225|C2349179|C0871208|C0205281|C0006826|C1511790|C0695347|C0557651|C0168634|C0679646|C0441889|C1704788|C1264633|C0679646|C0205281|C0006826|C0442726|C0695347|C0205145|C0011923|C1704258|C1711411|C0030664|C0444669|C0005558|C0543467|C0015252
In children given the spray the rate of recurrence during the three months of follow up was significantly reduced compared with those given placebo.,In children spray rate recurrence months follow reduced compared placebo.,G0000000|C0008059|C1704413|C0871208|C0034897|C0439231|C0332283|C0392756|C1707455|C0032042
"Dysphagia status was measured by the Functional Dysphagia Scale (FDS), the Penetration-Aspiration Scale (PAS), and the Dysphagia Outcome and Severity Scale (DOSS) using the results of a videofluoroscopic swallowing study.","Dysphagia status measured Functional Dysphagia Scale (FDS), Penetration-Aspiration Scale (PAS), Dysphagia Outcome Severity Scale (DOSS) videofluoroscopic swallowing study.",C0011168|C0449438|C0444706|C0205245|C0011168|C0175659|G0000000|C0205321|C0175659|C0030125|C0011168|C1274040|C0439793|C0175659|C1692318|C1660599|C0011167|C0557651
"The primary outcomes analyzed were STH infection prevalence, stunting prevalence (height-for-age z-score [HAZ] < −2), underweight prevalence (weight-for-age z-score [WAZ] < −2), WMI, PSI, school attendance, and normalized TIMSS mathematics test scores.","The primary outcomes analyzed STH infection prevalence, stunting prevalence (height-for-age z-score [HAZ] < −2), underweight prevalence (weight-for-age z-score [WAZ] < −2), WMI, PSI, school attendance, normalized TIMSS mathematics test scores.",G0000000|C0205225|C1274040|C0936012|C1846860|C0009450|C0033105|C0018273|C0033105|C0489786|C0871421|G0000000|G0000000|G0000000|C0041667|C0033105|C0005910|C0871421|G0000000|G0000000|G0000000|G0000000|G0000000|C0036375|C2827364|C1882115|G0000000|C0024934|C0022885|C0449820
"Primary efficacy was based on clinical and mycologic assessment of tinea lesion at baseline, end of ‘Treatment Phase’ and end of Follow-up Phase (2 weeks following completion of the treatment).","Primary efficacy based clinical mycologic assessment tinea lesion baseline, ‘Treatment Phase’ Follow-up Phase (2 weeks completion treatment).",C0205225|C1280519|C1527178|C0205210|C0205467|C1261322|C0040247|C0221198|C0168634|G0000000|G0000000|C0589120|C0205390|G0000000|C0439230|C0205197|C0039798
A secondary outcome was 30-day abstinence at 10 weeks.,A secondary outcome 30-day abstinence 10 weeks.,G0000000|C0027627|C1274040|C0450371|C3843422|C0450371|C0439230
"There was no between-group difference in the primary outcome measure, 30-day Comprehensive Complications Index (adjusted mean difference, –3.2; 95% CI, –11.8 to 5.3; P = .45).","There between-group difference primary outcome measure, 30-day Comprehensive Complications Index (adjusted difference, –3.2; 95% CI, –11.8 5.3; P = .45).",G0000000|C0441833|C1705241|C0205225|C1274040|C0079809|C0450371|C1880156|C0009566|C0918012|C0456081|C1705241|G0000000|C0450371|C0008107|G0000000|G0000000|G0000000
"Secondary outcomes included the FMA scale for motor functions, the rate of recovery based on the bedside swallowing assessment (BSA) and the videofluoroscopic swallowing study (VFSS) for swallowing function, the mini-mental state examination (MMSE) and Montreal cognitive assessment (MoCA) for cognitive function, and adverse reaction of acupuncture for safety evaluation.","Secondary outcomes included FMA scale motor functions, rate recovery based bedside swallowing assessment (BSA) videofluoroscopic swallowing study (VFSS) swallowing function, mini-mental examination (MMSE) Montreal cognitive assessment (MoCA) cognitive function, adverse reaction acupuncture safety evaluation.",C0027627|C1274040|C0332257|C2332774|C0175659|C1513492|C0542341|C0871208|C0237820|C1527178|G0000000|C0011167|C1261322|G0000000|C1660599|C0011167|C0557651|G0000000|C0011167|C0031843|C0445542|G0000000|C0451306|G0000000|C1516691|C1261322|C3541265|C1516691|C0031843|G0000000|C0443286|C0001299|C0036043|C0220825
"Overall, 22 (42%) of the children given spray experienced no acute otitis media during the study and had a normal tympanic membrane at the last valid visit compared with 12 (22%) of the children given placebo (table).","Overall, 22 (42%) children spray experienced acute otitis media study normal tympanic membrane valid visit compared 12 (22%) children placebo (table).",C0282416|C0450371|C0450371|C0008059|C1704413|C0237607|C0205178|C0029877|C0009458|C0557651|C0205307|C0041445|C0025255|C2349099|C0545082|C1707455|C0450371|C0450371|C0008059|C0032042|C0039224
Completion status did not differ between groups (P = .26).,Completion status (P = .26).,C0205197|C0449438|C0369773|G0000000|C0450371
"The primary outcome was blindly measured with National Institutes of Health Stroke Scale (NIHSS) at week 1, week 3, and week 7.","The primary outcome blindly measured National Institutes Health Stroke Scale (NIHSS) week 1, week 3, week 7.",G0000000|C0205225|C1274040|G0000000|C0444706|C3245503|C0021622|C0018684|C0038454|C0175659|C3476804|C0332174|G0000000|C0332174|G0000000|C0332174|G0000000
Outcome was short-term (from Week 6 to Month 4) and long-term (from Month 6 to Month 12) abstinence or reduction.,Outcome short-term (from Week 6 Month 4) long-term (from Month 6 Month 12) abstinence reduction.,C1274040|C0443303|G0000000|C0332174|G0000000|C0332177|G0000000|C0443252|G0000000|C0332177|G0000000|C0332177|C0450371|C3843422|C0301630
"QOL was measured using four validated instruments: the Symptom Distress Scale (SDS), the Brief Fatigue Inventory (BFI), the Functional Assessment of Cancer Therapy-Anemia (FACT-An), and the Linear Analog Scale Assessment (LASA).16 Study visits occurred at baseline and at the end of weeks 3, 6, 9, 12, and 15 (end of study).","QOL measured validated instruments: Symptom Distress Scale (SDS), Brief Fatigue Inventory (BFI), Functional Assessment Cancer Therapy-Anemia (FACT-An), Linear Analog Scale Assessment (LASA).16 Study visits occurred baseline weeks 3, 6, 9, 12, 15 (end study).",C0518214|C0444706|G0000000|C0348000|C1457887|C0231303|C0175659|C3813719|C1282927|C0015672|C0021941|C2698562|C0205245|C1261322|C0006826|C0039798|G0000000|C0205132|C0243071|C0175659|C1261322|C0065034|C0557651|C0545082|C1709305|C0168634|C0439230|G0000000|G0000000|G0000000|C0450371|C0450371|C0444930|C0557651
"QOL raw scores were calculated, and QOL scores were also transformed to represent the position along the theoretical range of the QOL dimension expressed as a percentage (0% to 100%).","QOL raw scores calculated, QOL scores transformed represent position theoretical range QOL dimension expressed percentage (0% 100%).",C0518214|C0001884|C0449820|C0444686|C0518214|C0449820|C1510411|C1882932|C0733755|C0871935|C1514721|C0518214|C0439534|G0000000|C0439165|G0000000|C1442061
No significant differences in adverse events occurred between the 3 groups (p > 0.05).,No differences adverse events occurred 3 (p > 0.05).,G0000000|C1705241|G0000000|C0441471|C1709305|G0000000|C0369773|G0000000|C0450371
"Secondary outcomes were 30-day overall and severe complications, primary and total length of hospital stay, 30-day emergency department visits and hospital readmissions, recovery of walking capacity, and patient-reported outcome measures.","Secondary outcomes 30-day severe complications, primary total length hospital stay, 30-day emergency department visits hospital readmissions, recovery walking capacity, patient-reported outcome measures.",C0027627|C1274040|C0450371|C0205082|C0009566|C0205225|C0439175|C1444754|C0019994|G0000000|C0450371|C0013956|C1704729|C0545082|C0019994|G0000000|C0237820|C0080331|C1516240|C0747307|C1274040|C0079809
"Serious adverse events (severe, life threatening or fatal) were common in this population (Table 2), but no specific types occurred more frequently in the inositol groups compared to placebo.","Serious adverse events (severe, life threatening fatal) common population (Table 2), specific types occurred frequently inositol compared placebo.",C0205404|G0000000|C0441471|C0205082|C0376558|G0000000|C1302234|C0205214|C0032659|C0039224|G0000000|C0205369|C0332307|C1709305|C0332183|C0021547|C1707455|C0032042
"The unfavorable primary outcome was type 1 ROP, which was defined as meeting the criteria for ophthalmological intervention to prevent retinal detachment, a more severe ROP type than ROP type 1 (eg, aggressive posterior ROP or rush disease), or death before the ROP outcome could be determined.","The unfavorable primary outcome type 1 ROP, defined meeting criteria ophthalmological intervention prevent retinal detachment, severe ROP type ROP type 1 (eg, aggressive posterior ROP rush disease), death ROP outcome determined.",G0000000|C3640815|C0205225|C1274040|C0332307|G0000000|C0035344|C1704788|C0556656|C0243161|C0029087|C0886296|C0309872|C0035298|C0541879|C0205082|C0035344|C0332307|C0035344|C0332307|G0000000|C0013715|C0001807|C0205095|C0035344|C0443052|C0012634|C0011065|C0035344|C1274040|G0000000
"Periodic treatment with albendazole given twice a year as a part of child health services in Uganda led to a 10% extra gain in weight of about 166 g per child per year compared with untreated controls, or an extra weight gain of around 5% if children were treated annually.","Periodic treatment albendazole child health services Uganda led 10% extra gain weight 166 child compared untreated controls, extra weight gain 5% children treated annually.",C0332182|C0039798|C0001911|C0008059|C0018684|C0557854|C0041573|C1708698|C0450371|G0000000|C1517378|C0005910|C1442061|C0008059|C1707455|C0332155|C0243148|G0000000|C0005910|C1517378|G0000000|C0008059|C1522326|C0332181
"Furthermore, 10 (31%) of the 32 children without recurrence who were given the spray had secretory otitis media at the last valid visit compared with 15 (56%) of the 27 children in the placebo group.","Furthermore, 10 (31%) 32 children recurrence spray secretory otitis media valid visit compared 15 (56%) 27 children placebo group.",G0000000|C0450371|C0450371|C0450371|C0008059|C0034897|C1704413|C1327616|C0029877|C0009458|C2349099|C0545082|C1707455|C0450371|C0450371|C0450371|C0008059|C0032042|C0441833
The swallowing function of the NMES/TDT group was significantly improved compared with the TDT group in all periods.,The swallowing function NMES/TDT improved compared TDT periods.,G0000000|C0011167|C0031843|C2985393|C0184511|C1707455|C3887634|C0439531
"(a) On day 3 after study entry the following assessments are performed: • Blood pressure (3 readings) • National Institute of Health Stroke Scale (b) On day 7 (+/- 1 day) after study entry the following assessments are performed: • Blood pressure (3 readings) • National Institute of Health Stroke Scale • Barthel ADL Index • Modified Rankin Scale • Blood test for renal function, (urea, creatinine) If a participant is discharged before day 3 or 7 following study entry, they will be asked to attend the outpatient department for data collection.","(a) On day 3 study entry assessments performed: • Blood pressure (3 readings) • National Institute Health Stroke Scale (b) On day 7 (+/- 1 day) study entry assessments performed: • Blood pressure (3 readings) • National Institute Health Stroke Scale • Barthel ADL Index • Modified Rankin Scale • Blood test renal function, (urea, creatinine) If participant discharged day 3 7 study entry, attend outpatient department data collection.",G0000000|G0000000|C0332173|G0000000|C0557651|C1705654|C1261322|C0884358|G0000000|C0005767|C0033095|G0000000|C0034754|G0000000|C3245503|C0021622|C0018684|C0038454|C0175659|G0000000|G0000000|C0332173|G0000000|G0000000|G0000000|C0332173|C0557651|C1705654|C1261322|C0884358|G0000000|C0005767|C0033095|G0000000|C0034754|G0000000|C3245503|C0021622|C0018684|C0038454|C0175659|G0000000|G0000000|C0001288|C0918012|G0000000|C0392747|G0000000|C0175659|G0000000|C0005767|C0022885|C0022646|C0031843|C0041942|C0010294|G0000000|C0679646|C0030685|C0332173|G0000000|G0000000|C0557651|C1705654|C1999232|C0029921|C1704729|C1511726|C1516698
The primary outcome is self-reported thirty-day abstinence at six months.,The primary outcome self-reported thirty-day abstinence months.,G0000000|C0205225|C1274040|C0681906|C1710392|C3843422|C0439231
"There were also no differences in the proportion of patients requiring red cell transfusions, changes in quality of life, or the dose of darbepoetin administered.","There differences proportion patients requiring red cell transfusions, quality life, dose darbepoetin administered.",G0000000|C1705241|C1709707|C0030705|G0000000|C0332575|C0007634|C0005841|C0332306|C0376558|C0178602|G0000000|C1521801
"However the weighted difference between the intervention and control villages for the incidence density of P. falciparum was not statistically significant (weighted mean difference of −2.6 episodes per 1,000 weeks at risk, (95% Confidence Interval; -7 to 1.8); p = 0.22).","However weighted difference intervention control villages incidence density P. falciparum statistically (weighted difference −2.6 episodes 1,000 weeks risk, (95% Confidence Interval; -7 1.8); p = 0.22).",G0000000|C0005910|C1705241|C0886296|C0243148|C0562518|C0021149|C0178587|C0369773|G0000000|C0038215|C0005910|C1705241|G0000000|C0332189|C1442061|C0439230|C0035647|C0450371|C0237529|C1272706|G0000000|G0000000|G0000000
"Primary outcomes were immune response at age 5 years to BCG and tetanus immunisation, and incidence of malaria, diarrhoea, pneumonia, measles, and tuberculosis during childhood.","Primary outcomes immune response age 5 BCG tetanus immunisation, incidence malaria, diarrhoea, pneumonia, measles, tuberculosis childhood.",C0205225|C1274040|C0439662|C0871261|C0001779|G0000000|G0000000|C0039614|C0020971|C0021149|C0024530|C0011991|C0032285|C0025007|C0041296|C0231335
We evaluated the Functional Dysphagia Scale (FDS) and the Penetration Aspiration Scale (PAS) with a videofluoroscopic swallowing study before and after rTMS.,We evaluated Functional Dysphagia Scale (FDS) Penetration Aspiration Scale (PAS) videofluoroscopic swallowing study rTMS.,G0000000|C0220825|C0205245|C0011168|C0175659|G0000000|C0205321|C0220787|C0175659|C0030125|C1660599|C0011167|C0557651|G0000000
Our results show that the intervention significantly reduced both infection prevalence and infection intensity relative to the control group.,Our intervention reduced infection prevalence infection intensity relative control group.,G0000000|C0886296|C0392756|C0009450|C0033105|C0009450|C0522510|C0080103|C0243148|C0441833
"In conclusion, NRT (nicotine gum or inhaler) doubled the quit rate compared to placebo and was safe.","In conclusion, NRT (nicotine gum inhaler) doubled quit rate compared placebo safe.",G0000000|C1707478|C1278444|C0028040|C0017562|C0021461|C0205173|C0748223|C0871208|C1707455|C0032042|G0000000
"During hospitalization there were no significant differences between groups in the rates of expected preterm diagnoses as a whole (Table 3), nor between groups in the upper or lower GA strata.","During hospitalization differences rates expected preterm diagnoses (Table 3), upper lower GA strata.",G0000000|C0019993|C1705241|C0871208|C1517001|C0151526|C0011900|C0039224|G0000000|C1282910|C0441994|C0016993|G0000000
"Our results suggest that individuals who never drank green tea have an elevated lung cancer risk compared to those who drank green tea at least one cup per day, and the effect is more pronounced in smokers.","Our individuals drank green tea elevated lung cancer risk compared drank green tea cup day, pronounced smokers.",G0000000|C0027361|C0452428|C0332583|C0039400|C0205250|C0024109|C0006826|C0035647|C1707455|C0452428|C0332583|C0039400|C1533124|C0332173|G0000000|C0337664
No differences in distribution of the bacteria were found between the spray and placebo groups.,No differences distribution bacteria spray placebo groups.,G0000000|C1705241|C0520511|C0004611|C1704413|C0032042|C0441833
"Baseline Demographic and Clinical Characteristics of Evaluable Patients Abbreviations: SD, standard deviation; Hb, hemoglobin; QOL, quality of life; LASA, Linear Analogue Self Assessment; BFI, Brief Fatigue Inventory.","Baseline Demographic Clinical Characteristics Evaluable Patients Abbreviations: SD, standard deviation; Hb, hemoglobin; QOL, quality life; LASA, Linear Analogue Self Assessment; BFI, Brief Fatigue Inventory.",C0168634|C0011298|C0205210|C1521970|C1516986|C0030705|C0000723|C2699239|C1442989|C0012727|C0019046|C0019046|C0518214|C0332306|C0376558|C0065034|C0205132|C0243071|C0036588|C1261322|C2698562|C1282927|C0015672|C0021941
"No significant changes were found in serum electrolytes, BUN, or Alb between both groups.","No serum electrolytes, BUN, Alb groups.",G0000000|C0229671|C0013832|G0000000|G0000000|C0441833
"Malaria infections, palpable splenomegaly, haemoglobin concentrations, and weight for height, did not differ significantly during the study period between villages with and without ITNs.","Malaria infections, palpable splenomegaly, haemoglobin concentrations, weight height, study period villages ITNs.",C0024530|C3714514|C0522499|C0038002|C0019046|C0086045|C0005910|C0489786|C0557651|C0439531|C0562518|G0000000
"The primary outcome was the CCI, which integrates all complications with their respective severities on a continuous scale ranging from 0 (no burden due to complications) to 100 (death as a result of complications).","The primary outcome CCI, integrates complications respective severities continuous scale ranging 0 (no burden complications) 100 (death result complications).",G0000000|C0205225|C1274040|C1861617|G0000000|C0009566|G0000000|C0439793|C0549178|C0175659|C1514721|G0000000|G0000000|C2828008|C0009566|C1442061|C0011065|C1274040|C0009566
The primary outcome was the NIHSS and modified Rankin scales at 90 days.,The primary outcome NIHSS modified Rankin scales 90 days.,G0000000|C0205225|C1274040|C3476804|C0392747|G0000000|C0175659|C0450371|C0439228
Our primary finding is that physicians who received the intervention were more likely to perform the 5As.,Our primary finding physicians received intervention perform 5As.,G0000000|C0205225|C0037088|C0031831|C1514756|C0886296|C0884358|G0000000
The favorable primary outcome was survival with only milder ROP or no ROP.,The favorable primary outcome survival milder ROP ROP.,G0000000|C3640814|C0205225|C1274040|C0038952|C2945599|C0035344|C0035344
There were no observed differences between treatment groups regarding serum CA-125 level after the first three cycles of chemotherapy.,There observed differences treatment serum CA-125 level cycles chemotherapy.,G0000000|C1441672|C1705241|C0039798|C0229671|C3887642|C0441889|C1511572|C0013216
Results from the present study showed that four-monthly treatments with albendazole reduced the prevalence of A. lumbricoides by 40.2% in the treatment group after 12 months.,Results study four-monthly treatments albendazole reduced prevalence A. lumbricoides 40.2% treatment 12 months.,C1274040|C0557651|C0205450|C0087111|C0001911|C0392756|C0033105|G0000000|G0000000|C0450371|C0039798|C0450371|C0439231
The key secondary end point was progression-free survival (PFS) assessed by BICR in the intent-to-treat population.,The key secondary progression-free survival (PFS) assessed BICR intent-to-treat population.,G0000000|G0000000|C0027627|C0242656|C0038952|C0242792|C1516048|G0000000|C0162425|C0032659
"Secondary endpoints were mortality from all breast cancers diagnosed after randomisation until the data cutoff date, all-cause mortality (in the entire trial population and in the subgroup of women with breast cancer), mortality from causes other than breast cancer (in the entire trial population and in the subgroup of women with breast cancer), and incidence of breast cancer.","Secondary endpoints mortality breast cancers diagnosed randomisation data cutoff date, all-cause mortality (in entire trial population subgroup women breast cancer), mortality breast cancer (in entire trial population subgroup women breast cancer), incidence breast cancer.",C0027627|C2349179|C0026565|C0006141|C0006826|C0011900|C0034656|C1511726|C1442160|C0011008|C0015127|C0026565|G0000000|C0439751|C0008976|C0032659|C1079230|C0043210|C0006141|C0006826|C0026565|C0006141|C0006826|G0000000|C0439751|C0008976|C0032659|C1079230|C0043210|C0006141|C0006826|C0021149|C0006141|C0006826
The primary end point was objective response rate (ORR) in the measurable disease analysis set assessed by blinded independent central review (BICR).,The primary objective response rate (ORR) measurable disease analysis set assessed blinded independent central review (BICR).,G0000000|C0205225|C0018017|C0871261|C0871208|G0000000|C1513040|C0012634|C0002778|C0036849|C1516048|C0150108|C0085862|C0205099|C0282443|G0000000
"Additional secondary endpoints of the study that are not included in this report comprise participant-reported outcomes, tumor biology by genomic profiles, PPV and additional-imaging-recommendation rates of the second screening round, and the 3-year incident cancer rate.","Additional secondary endpoints study included report comprise participant-reported outcomes, tumor biology genomic profiles, PPV additional-imaging-recommendation rates screening round, 3-year incident cancer rate.",C1524062|C0027627|C2349179|C0557651|C0332257|C0684224|C2700400|C0679646|C1274040|C0027651|C0005532|C0017428|C1979963|C1514243|C1524062|C0871208|C0220908|C0332490|C0439234|C1551358|C0006826|C0871208
The primary outcome was prevalence and intensity of STHs.,The primary outcome prevalence intensity STHs.,G0000000|C0205225|C1274040|C0033105|C0522510|C1846860
"Secondary end points included OS; safety; and immunologic parameters, including human antimouse antibody (HAMA), Ab3, Ab1′, and serum CA-125 (blinded during study).","Secondary included OS; safety; immunologic parameters, including human antimouse antibody (HAMA), Ab3, Ab1′, serum CA-125 (blinded study).",C0027627|C0332257|C0229090|C0036043|C0152036|C0449381|C0332257|C0086418|C1979849|C0003241|C1291910|G0000000|G0000000|C0229671|C3887642|C0150108|C0557651
Worst joint pain scores decreased by 1.6 points (29%) at 12 months among women randomly assigned to exercise versus a 0.2-point increase (3%) among those receiving usual care (n = 60; P < .001).,Worst joint pain scores decreased 1.6 (29%) 12 months women randomly assigned exercise versus 0.2-point increase (3%) receiving usual care (n = 60; P < .001).,C1522166|C0022417|C0030193|C0449820|C0205216|G0000000|C0450371|C0450371|C0439231|C0043210|G0000000|C1516050|C0015259|G0000000|C1552961|C0442805|G0000000|C1514756|C3538928|C1947933|C0369718|G0000000|C0450371|C0369773|G0000000|C1442061
Secondary end point: overall survival distribution against time.,Secondary point: survival distribution time.,C0027627|C1552961|C0038952|C0520511|C0040223
Our primary outcome was prolonged abstinence at the 7.5-month assessment (6 months postenrollment plus a 6-week grace period).,Our primary outcome prolonged abstinence 7.5-month assessment (6 months postenrollment 6-week grace period).,G0000000|C0205225|C1274040|C0439590|C3843422|C0332177|C1261322|G0000000|C0439231|G0000000|C0332174|G0000000|C0439531
"Complete blood counts were measured weekly; QOL was assessed and iron parameters (ferritin, transferrin saturation, and soluble transferrin receptor) measured at baseline, at the end of week 6, and at the end of study.","Complete blood counts measured weekly; QOL assessed iron parameters (ferritin, transferrin saturation, soluble transferrin receptor) measured baseline, week 6, study.",C0205197|C0005767|C0439157|C0444706|C0332174|C0518214|C1516048|C0302583|C0449381|C0015879|C0040679|C0522534|C1749467|C0040679|C0597357|C0444706|C0168634|C0332174|G0000000|C0557651
"In conclusion, recolonisation with α streptococci with inhibitory activity against common pathogens of otitis media significantly diminishes the recurrence rate of this condition in susceptible children.","In conclusion, recolonisation α streptococci inhibitory activity common pathogens otitis media diminishes recurrence rate condition susceptible children.",G0000000|C1707478|G0000000|G0000000|C0038402|C3463820|C0205177|C0205214|C0450254|C0029877|C0009458|C0205216|C0034897|C0871208|C0012634|C0220898|C0008059
Outcomes of the VFSS were assessed using the Functional Oral Intake Scale (FOIS).,Outcomes VFSS assessed Functional Oral Intake Scale (FOIS).,C1274040|G0000000|C1516048|C0205245|C0442027|C1512806|C0175659|C0086325
"Significant difference in gain of weight, length and head circumference was found in intervention group compared with Controls, P<0.05 (Table 2).","Significant difference gain weight, length head circumference intervention compared Controls, P<0.05 (Table 2).",C0237881|C1705241|C1517378|C0005910|C1444754|C0018670|C0332520|C0886296|C1707455|C0243148|C0369773|C0039224|G0000000
We specified two co-primary outcomes: school attendance and educational attainment in end-of-year examinations.,We co-primary outcomes: school attendance educational attainment end-of-year examinations.,G0000000|C3245499|C1274040|C0036375|C2827364|C0587721|G0000000|C0444930|C0031809
Secondary end points were PFS as assessed by BICR; investigator-assessed PFS; time from random assignment to second progression or death (PFS2); overall survival (OS); time from random assignment to first subsequent therapy or death (TFST); time to earliest progression by RECIST or cancer antigen-125 (CA-125) or death (Data Supplement); and time from random assignment to study treatment discontinuation or death (TDT).,Secondary PFS assessed BICR; investigator-assessed PFS; time random assignment progression death (PFS2); survival (OS); time random assignment subsequent therapy death (TFST); time earliest progression RECIST cancer antigen-125 (CA-125) death (Data Supplement); time random assignment study treatment discontinuation death (TDT).,C0027627|C0242792|C1516048|G0000000|C0035173|C0242792|C0040223|C0034656|C1516050|C0242656|C0011065|G0000000|C0038952|C0229090|C0040223|C0034656|C1516050|C0332282|C0039798|C0011065|G0000000|C0040223|C1279919|C0242656|C1709926|C0006826|C0003320|C3887642|C0011065|C1511726|C0242295|C0040223|C0034656|C1516050|C0557651|C0039798|C0457454|C0011065|C3887634
The between-group differences for presence of any ROP outcome and the type 2 ROP or greater outcome were not significantly different.,The between-group differences presence ROP outcome type 2 ROP outcome different.,G0000000|C0441833|C1705241|C0150312|C0035344|C1274040|C0332307|G0000000|C0035344|C1274040|C1705242
"Binomial erythropoietic (Hb) response rates were similar between groups: 69.5% (exact 95% binomial CI, 61.9% to 76.5%) of IV iron-treated patients achieved a Hb response compared with 66.9% (95% CI, 59.1% to 74.0%) receiving oral iron and 65.0% (95% CI, 57.2% to 72.3%) receiving oral placebo (P = .75; Fig 2).","Binomial erythropoietic (Hb) response rates groups: 69.5% (exact 95% binomial CI, 61.9% 76.5%) IV iron-treated patients achieved Hb response compared 66.9% (95% CI, 59.1% 74.0%) receiving oral iron 65.0% (95% CI, 57.2% 72.3%) receiving oral placebo (P = .75; Fig 2).",G0000000|C0312829|C0019046|C0871261|C0871208|C0441833|C0450371|C2828393|C0450371|G0000000|C0008107|C0450371|C0450371|C0022326|C0302583|C0030705|G0000000|C0019046|C0871261|C1707455|C0450371|C0450371|C0008107|C0450371|C0450371|C1514756|C0442027|C0302583|C0450371|C0450371|C0008107|C0450371|C0450371|C1514756|C0442027|C0032042|C0369773|G0000000|C0450371|C0349966|G0000000
The primary study end point was recurrence-free survival (RFS) at the end of double-blind observation.,The primary study recurrence-free survival (RFS) double-blind observation.,G0000000|C0205225|C0557651|C0034897|C0038952|C0341703|C0013072|C0302523
"To evaluate the degree of improvement in dysphagia, the Functional Dysphagia Scale (FDS), the Penetration-Aspiration Scale (PAS), and the Dysphagia Outcome and Severity Scale (DOSS) were measured based on the VFSS results.","To evaluate degree improvement dysphagia, Functional Dysphagia Scale (FDS), Penetration-Aspiration Scale (PAS), Dysphagia Outcome Severity Scale (DOSS) measured based VFSS results.",C0040363|C0220825|C0441889|C2986411|C0011168|C0205245|C0011168|C0175659|G0000000|C0205321|C0175659|C0030125|C0011168|C1274040|C0439793|C0175659|C1692318|C0444706|C1527178|G0000000|C1274040
Statistically significant differences in pain severity and pain interference were also observed between exercisers versus the usual-care group (both P < .001).,Statistically differences pain severity pain interference observed exercisers versus usual-care (both P < .001).,C0038215|C1705241|C0030193|C0439793|C0030193|C0521102|C1441672|C0180776|G0000000|C3538928|G0000000|C0369773|G0000000|C1442061
"The effect of the intervention on patient-reported outcome measures (PROMs) targeted between-group differences in generic health status (36-Item Short Form Survey), anxiety and depression (Hospital Anxiety and Depression Scale), and self-reported energy expenditure (Community Healthy Activities Model Program for Seniors questionnaire).","The intervention patient-reported outcome measures (PROMs) targeted between-group differences generic health status (36-Item Short Form Survey), anxiety depression (Hospital Anxiety Depression Scale), self-reported energy expenditure (Community Healthy Activities Model Program Seniors questionnaire).",G0000000|C0886296|C0747307|C1274040|C0079809|C0015944|C1521840|C0441833|C1705241|C0085155|C0018684|C0449438|C0450371|C1282927|C0348078|C0038951|C0003467|C0011570|C0019994|C0003467|C0011570|C0175659|C0681906|C0424589|C0015316|C0009462|C3898900|C0441655|C3161035|C1709697|C1456594|C0034394
"Significant improvements from acupuncture treatment were observed in NIHSS (p < 0.001), VFSS (p < 0.001), MMSE (p < 0.001), MoCA (p = 0.001), but not obtained from FMA (p = 0.228).","Significant improvements acupuncture treatment observed NIHSS (p < 0.001), VFSS (p < 0.001), MMSE (p < 0.001), MoCA (p = 0.001), FMA (p = 0.228).",C0237881|C2986411|C0001299|C0039798|C1441672|C3476804|C0369773|G0000000|G0000000|G0000000|C0451306|C0369773|G0000000|C3541265|G0000000|C2332774|G0000000
"Neurological and cardiac status, including NIHSS score, was assessed at 24 and 48 hours and at 7 days or discharge, whichever came first.","Neurological cardiac status, including NIHSS score, assessed 24 48 hours 7 days discharge, whichever first.",C0205494|C0018787|C0449438|C0332257|C3476804|C0449820|C1516048|C0450371|C0450371|C0439227|G0000000|C0439228|C0012621|G0000000|C0205435
"Human milk fortification with PDF resulted in better growth with increase in weight 16.8 and 13.78 g/kg/day (P=0.0430), length 0.76 and 0.58 cm/week (P=0.0027), and head circumference of 0.59 and 0.5 cm/week (P=0.0217) in cases and controls respectively.","Human milk fortification PDF growth increase weight 16.8 13.78 g/kg/day (P=0.0430), length 0.76 0.58 cm/week (P=0.0027), head circumference 0.59 0.5 cm/week (P=0.0217) controls respectively.",C0086418|C0026131|G0000000|C1431343|C0018270|C0442805|C0005910|C0450371|C0450371|C1532536|C0369773|C1444754|C0450371|C0450371|C0332174|C0369773|C0018670|C0332520|C0450371|G0000000|C0332174|C0369773|C0243148|G0000000
This showed no statistical difference in the risk of death between patients receiving abagovomab versus placebo.,This statistical difference risk death patients receiving abagovomab versus placebo.,G0000000|C0038215|C1705241|C0035647|C0011065|C0030705|C1514756|C1832044|G0000000|C0032042
Main outcome measure Weight gain.,Main outcome measure Weight gain.,C0205225|C1274040|C0079809|C0005910|C1517378
"For all four of the QOL instruments used—FACT-An, LASA, BFI, and SDS—there were no significant differences in the QOL change between the three arms during the course of the study.","For QOL instruments used—FACT-An, LASA, BFI, SDS—there differences QOL change arms study.",G0000000|C0518214|C0348000|G0000000|C0065034|C2698562|G0000000|C1705241|C0518214|C0392747|C0206655|C0557651
"The malnutrition prevalences at the end of the study were not significantly different comparing NN and ITN clusters, either for all children under 10 years (− 1.7% (95% CI; - 3.8, 0.4), p = 0.094), or for the children under five years of age (− 1.8% (95% CI; - 5.9, 2.3), p = 0.35) (Additional file 9).","The malnutrition prevalences study comparing NN ITN clusters, children 10 (− 1.7% (95% CI; - 3.8, 0.4), p = 0.094), children age (− 1.8% (95% CI; - 5.9, 2.3), p = 0.35) (Additional file 9).",G0000000|C0162429|C0033105|C0557651|C1707455|C0027779|G0000000|C1555715|C0008059|C0450371|G0000000|G0000000|C0450371|C0008107|G0000000|G0000000|G0000000|G0000000|C0008059|C0001779|G0000000|G0000000|C0450371|C0008107|G0000000|G0000000|G0000000|G0000000|C1524062|C0016094|G0000000
"Albendazole during pregnancy caused an increased rate of eczema in the children (HR 1.58 (95% CI 1.15–2.17), p = 0.005).","Albendazole pregnancy caused increased rate eczema children (HR 1.58 (95% CI 1.15–2.17), p = 0.005).",C0001911|C0032961|C0015127|C0205217|C0871208|C0013595|C0008059|G0000000|C0450371|C0450371|C0008107|G0000000|G0000000
"Adverse events and co-morbidities were fewer in the inositol groups, but not significantly so.","Adverse events co-morbidities fewer inositol groups, so.",G0000000|C0441471|C0009488|C0205388|C0021547|C0441833|C0037640
The primary end point was ORR as assessed by blinded independent central review (BICR) in the measurable disease analysis set (MDAS) using RECIST version 1.1.,The primary ORR assessed blinded independent central review (BICR) measurable disease analysis set (MDAS) RECIST version 1.1.,G0000000|C0205225|G0000000|C1516048|C0150108|C0085862|C0205099|C0282443|G0000000|C1513040|C0012634|C0002778|C0036849|C0000379|C1709926|C0333052|G0000000
"To evaluate the swallowing function of patients with dysphagia, functional dysphagia scale (FDS), penetration-aspiration scale (PAS), vallecular residue (VR), and pyriform sinuses residue (PR) were assessed.","To evaluate swallowing function patients dysphagia, functional dysphagia scale (FDS), penetration-aspiration scale (PAS), vallecular residue (VR), pyriform sinuses residue (PR) assessed.",C0040363|C0220825|C0011167|C0031843|C0030705|C0011168|C0205245|C0011168|C0175659|G0000000|C0205321|C0175659|C0030125|C0227157|C1709915|C3476815|G0000000|C0016169|C1709915|C0279759|C1516048
"The main outcome measure was weight gain, calculated as the difference in weight between the first and last child health day for each child.","The main outcome measure weight gain, calculated difference weight child health day child.",G0000000|C0205225|C1274040|C0079809|C0005910|C1517378|C0444686|C1705241|C0005910|C0008059|C0018684|C0332173|C0008059
"Intervention effects were evaluated using mixed-model repeated measures analysis, with change at 12 months as the primary end point.","Intervention effects evaluated mixed-model repeated measures analysis, change 12 months primary point.",C0886296|C1280500|C0220825|C0205430|C0205341|C0079809|C0002778|C0392747|C0450371|C0439231|C0205225|C1552961
The results of our study suggest the viability and effectiveness of tobacco cessation services delivered to low-income smokers via their dental health care practitioner in community health centers.,The study viability effectiveness tobacco cessation services delivered low-income smokers dental health care practitioner community health centers.,G0000000|C0557651|C0443348|C1280519|C0040329|C1880019|C0557854|C1705822|C0032854|C0337664|C0011365|C0018684|C1947933|C1709627|C0009462|C0018684|C0205099
The primary endpoint was mortality from breast cancers diagnosed in the intervention period of the trial.,The primary endpoint mortality breast cancers diagnosed intervention period trial.,G0000000|C0205225|C2349179|C0026565|C0006141|C0006826|C0011900|C0886296|C0439531|C0008976
"Of the 130 children included, 22 in the spray group had adverse events compared with 25 in the placebo group.","Of 130 children included, 22 spray adverse events compared 25 placebo group.",G0000000|C1442061|C0008059|C0332257|C0450371|C1704413|G0000000|C0441471|C1707455|C0450371|C0032042|C0441833
"[13] Other secondary outcomes were growth and anaemia assessed at routine annual visits, and cognitive development.","[13] Other secondary outcomes growth anaemia assessed routine annual visits, cognitive development.",C0450371|G0000000|C0027627|C1274040|C0018270|C0002871|C1516048|C0205547|C0332181|C0545082|C1516691|C0243107
"The results of the ATT analysis mirror those of the primary ITT analysis of the full sample of children: the intervention had a significant impact on reducing STH infection prevalence and infection intensity, but no impact on any of the other measured outcomes.","The ATT analysis mirror primary ITT analysis sample children: intervention impact reducing STH infection prevalence infection intensity, impact measured outcomes.",G0000000|G0000000|C0002778|C0181868|C0205225|G0000000|C0002778|C0370003|C0008059|C0886296|C1825598|C0392756|C1846860|C0009450|C0033105|C0009450|C0522510|C1825598|C0444706|C1274040
"The prevalences of anaemia at the end of the study were not significantly different comparing NN and ITN clusters (weighted mean difference of - 3.3% (95% CI; - 11.3, 4.7), p = 0.38 (Additional file 8).","The prevalences anaemia study comparing NN ITN clusters (weighted difference - 3.3% (95% CI; - 11.3, 4.7), p = 0.38 (Additional file 8).",G0000000|C0033105|C0002871|C0557651|C1707455|C0027779|G0000000|C1555715|C0005910|C1705241|G0000000|G0000000|C0450371|C0008107|G0000000|C0450371|G0000000|G0000000|C1524062|C0016094|G0000000
Inositol urine losses and feeding intakes were measured.,Inositol urine losses feeding intakes measured.,C0021547|C0042036|C1517945|C0204695|C1512806|C0444706
"There was a significant between-group (treatment versus control) difference in infection prevalence at follow-up (P = 0.026), with the prevalence of any STH infection at 31.4% (95% CI = 28.6–34.2%) in the control group and 27.7% (95% CI = 24.9–30.4%) in the intervention group (adjusted odds ratio in the intervention schools, 0.71; 95% CI = 0.52–0.96).","There between-group (treatment versus control) difference infection prevalence follow-up (P = 0.026), prevalence STH infection 31.4% (95% CI = 28.6–34.2%) control 27.7% (95% CI = 24.9–30.4%) intervention (adjusted odds ratio intervention schools, 0.71; 95% CI = 0.52–0.96).",G0000000|C0441833|C0039798|G0000000|C0243148|C1705241|C0009450|C0033105|C0589120|C0369773|G0000000|C1442061|C0033105|C1846860|C0009450|C0450371|C0450371|C0008107|G0000000|G0000000|C0243148|C0450371|C0450371|C0008107|G0000000|G0000000|C0886296|C0456081|G0000000|C0456603|C0886296|C0036375|C0450371|C0450371|C0008107|G0000000|G0000000
Secondary outcomes - worm infections and WAZ and HAZ at start of year 2 (1999),Secondary outcomes - worm infections WAZ HAZ start 2 (1999),C0027627|C1274040|G0000000|C0018889|C3714514|G0000000|G0000000|C0439659|G0000000|G0000000
Primary end point: recurrence-free survival distribution against time.,Primary point: recurrence-free survival distribution time.,C0205225|C1552961|C0034897|C0038952|C0520511|C0040223
Health-related quality of life (HRQoL) was assessed using the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy–Ovarian Cancer questionnaire.,Health-related quality life (HRQoL) assessed Trial Outcome Index (TOI) Functional Assessment Cancer Therapy–Ovarian Cancer questionnaire.,C0018684|C0332306|C0376558|G0000000|C1516048|C0008976|C1274040|C0918012|G0000000|C0205245|C1261322|C0006826|G0000000|C0006826|C0034394
The primary outcome measure was the incidence and prevalence of malaria in children.,The primary outcome measure incidence prevalence malaria children.,G0000000|C0205225|C1274040|C0079809|C0021149|C0033105|C0024530|C0008059
The primary outcome measure used to measure success at 6 months was continuous abstinence from the end of patch treatment.,The primary outcome measure measure success 6 months continuous abstinence patch treatment.,G0000000|C0205225|C1274040|C0079809|C0079809|C0597535|G0000000|C0439231|C0549178|C3843422|C0332461|C0039798
"The primary outcome was self-reports of cessation since the last visit via private questionnaire, confirmed by CO < 8 ppm.","The primary outcome self-reports cessation visit private questionnaire, confirmed CO < 8 ppm.",G0000000|C0205225|C1274040|C0681906|C1880019|C0545082|C0033175|C0034394|C0521093|C3245499|G0000000|G0000000|C0439187
"Daily weight, weekly length and frontal-occipital circumference were measured.","Daily weight, weekly length frontal-occipital circumference measured.",C0332173|C0005910|C0332174|C1444754|C0205123|C0332520|C0444706
"The primary efficacy variables including change in pruritus, erythema, vesicle, desquamation and mycological cure were significantly improved in all the three groups, as compared to baseline, in the Treatment and Follow-up phase.","The primary efficacy variables including change pruritus, erythema, vesicle, desquamation mycological cure improved groups, compared baseline, Treatment Follow-up phase.",G0000000|C0205225|C1280519|C0439828|C0332257|C0392747|C0033774|C0041834|C0005758|C0237849|C0205467|C1880198|C0184511|C0441833|C1707455|C0168634|C0039798|C0589120|C0205390
"Secondary end points included transfusion requirements, total ESA dose used, safety, and QOL.","Secondary included transfusion requirements, total ESA dose used, safety, QOL.",C0027627|C0332257|C0005841|C1514873|C0439175|C3890206|C0178602|C1273517|C0036043|C0518214
"The planned Phase 3 study primary outcome of meeting criteria for ROP surgery, or death before ROP outcome, among those infants eligible for that trial (<280/7 weeks GA) was highest in the placebo group and lower in the inositol groups (44%, 23%, 36%, and 19%, for the placebo, 10, 40, and 80mg/kg/day groups, respectively, p=0.29).","The planned Phase 3 study primary outcome meeting criteria ROP surgery, death ROP outcome, infants eligible trial (<280/7 weeks GA) placebo lower inositol (44%, 23%, 36%, 19%, placebo, 10, 40, 80mg/kg/day groups, respectively, p=0.29).",G0000000|C1301732|C0205390|G0000000|C0557651|C0205225|C1274040|C0556656|C0243161|C0035344|C0038894|C0011065|C0035344|C1274040|C0021270|C1548635|C0008976|C1442061|C0439230|C0016993|C0032042|C0441994|C0021547|C0450371|C0450371|C0450371|C0450371|C0032042|C0450371|C0450371|C0439418|C0441833|G0000000|C0369773
"In conclusion, given the efficacy of AIs in preventing breast cancer recurrence and the proportion of women who discontinue these drugs because of adverse events, interventions to improve adverse effects are important.","In conclusion, efficacy AIs preventing breast cancer recurrence proportion women discontinue drugs adverse events, interventions improve adverse effects important.",G0000000|C1707478|C1280519|G0000000|C0309872|C0006141|C0006826|C0034897|C1709707|C0043210|C1444662|C0013227|G0000000|C0441471|C0886296|G0000000|G0000000|C1280500|C3898777
"Results The provision of periodic anthelmintic treatment as a part of child health services in Uganda resulted in an increase in weight gain of about 10% (166 g per child per year, 95% confidence interval 16 to 316) above expected weight gain when treatments were given twice a year, and an increase of 5% when the treatment was given annually.","Results The provision periodic anthelmintic treatment child health services Uganda increase weight gain 10% (166 child year, 95% confidence interval 16 316) expected weight gain treatments year, increase 5% treatment annually.",C1274040|G0000000|C1549071|C0332182|C0003158|C0039798|C0008059|C0018684|C0557854|C0041573|C0442805|C0005910|C1517378|C0450371|C1442061|C0008059|C0439234|C0450371|C0237529|C1272706|C0450371|C1442061|C1517001|C0005910|C1517378|C0087111|C0439234|C0442805|G0000000|C0039798|C0332181
The rmANOVA analysis demonstrated that there was a statistically significant difference in epg between treatment and placebo groups.,The rmANOVA analysis demonstrated statistically difference epg treatment placebo groups.,G0000000|G0000000|C0002778|G0000000|C0038215|C1705241|C1825057|C0039798|C0032042|C0441833
"Pain severity and interference, as well as DASH and WOMAC pain scores, also decreased significantly at 12 months in women randomly assigned to exercise, compared with increases for those receiving usual care (all P < .001).","Pain severity interference, DASH WOMAC pain scores, decreased 12 months women randomly assigned exercise, compared increases receiving usual care (all P < .001).",C0030193|C0439793|C0521102|C2827624|G0000000|C0030193|C0449820|C0205216|C0450371|C0439231|C0043210|G0000000|C1516050|C0015259|C1707455|C0205217|C1514756|C3538928|C1947933|G0000000|C0369773|G0000000|C1442061
"Secondary efficacy was a ‘Composite Score’ of all clinical symptoms (pruritus, erythema, vesicle and desquamation); and ‘Physician Global Assessment’ based on three criteria; successful treatment outcome (clinical cure + negative mycology), clinical success (symptomatic relief + clinical cure) and clinical failure (no clinical and mycological improvement), at end of ‘Treatment Phase’ and ‘Follow-up Phase’.","Secondary efficacy ‘Composite Score’ clinical symptoms (pruritus, erythema, vesicle desquamation); ‘Physician Global Assessment’ based criteria; successful treatment outcome (clinical cure + negative mycology), clinical success (symptomatic relief + clinical cure) clinical failure (no clinical mycological improvement), ‘Treatment Phase’ ‘Follow-up Phase’.",C0027627|C1280519|G0000000|G0000000|C0205210|C0683368|C0033774|C0041834|C0005758|C0237849|G0000000|C0205246|G0000000|C1527178|C0243161|C0597535|C0039798|C1274040|C0205210|C1880198|G0000000|C0205160|C0026932|C0205210|C0597535|C0231220|C0564405|G0000000|C0205210|C1880198|C0205210|C0231174|G0000000|C0205210|C0205467|C2986411|G0000000|G0000000|G0000000|G0000000
"Both before and after rTMS, we evaluated the Functional Dysphagia Scale (FDS), the Penetration Aspiration Scale (PAS) using VFSS, and the American Speech-Language Hearing Association National Outcomes Measurements System Swallowing Scale (ASHA NOMS).","Both rTMS, evaluated Functional Dysphagia Scale (FDS), Penetration Aspiration Scale (PAS) VFSS, American Speech-Language Hearing Association National Outcomes Measurements System Swallowing Scale (ASHA NOMS).",G0000000|G0000000|C0220825|C0205245|C0011168|C0175659|G0000000|C0205321|C0220787|C0175659|C0030125|G0000000|C0596070|C0237113|C0018767|C0004083|C3245503|C1274040|C0242485|C0449913|C0011167|C0175659|G0000000|C1442113
We found that cases had younger age at full intake than controls (160 cc/kg/day) with significant difference (P=0.04).,We age intake controls (160 cc/kg/day) difference (P=0.04).,G0000000|C0001779|C1512806|C0243148|C1442061|C3538933|C1705241|C0369773
"The WOMAC total score for lower extremities decreased by 9.4 points (37% decrease) in women randomly assigned to exercise at 12 months, compared with a 0.5-point increase (2% increase) in the usual-care group (difference, 9.9; 95% CI, 2.8 to 16.9; P < .001).","The WOMAC total score lower extremities decreased 9.4 (37% decrease) women randomly assigned exercise 12 months, compared 0.5-point increase (2% increase) usual-care (difference, 9.9; 95% CI, 2.8 16.9; P < .001).",G0000000|G0000000|C0439175|C0449820|C0441994|C0015385|C0205216|G0000000|C0450371|C0392756|C0043210|G0000000|C1516050|C0015259|C0450371|C0439231|C1707455|C1552961|C0442805|G0000000|C0442805|C3538928|C1705241|G0000000|C0450371|C0008107|G0000000|C0450371|C0369773|G0000000|C1442061
There was no evidence of a diuretic effect of inositol as urine volumes measured between 3 and 5 ml/kg/hr and did not vary significantly by group (data not shown).,There evidence diuretic inositol urine volumes measured 3 5 ml/kg/hr vary (data shown).,G0000000|C3887511|C0012798|C0021547|C0042036|C0449468|C0444706|G0000000|G0000000|C1532580|G0000000|C1511726|C1547282
The results of the present study indicate that sertaconazole was better than terbinafine and luliconazole in relieving signs and symptoms of dermatophytoses especially pruritus thereby improving patients’ quality of life.,The study sertaconazole terbinafine luliconazole relieving signs symptoms dermatophytoses pruritus improving patients’ quality life.,G0000000|C0557651|C0074391|C0076110|C1956280|C0332303|C0220912|C0683368|C0011636|C0033774|C1272745|G0000000|C0332306|C0376558
"Primary outcomes were post-immunisation recall responses to BCG and tetanus antigens, and incidence of malaria, diarrhoea, and pneumonia; incidence of eczema was an important secondary outcome.","Primary outcomes post-immunisation recall responses BCG tetanus antigens, incidence malaria, diarrhoea, pneumonia; incidence eczema secondary outcome.",C0205225|C1274040|C0687676|C0034770|C0871261|G0000000|C0039614|C0003320|C0021149|C0024530|C0011991|C0032285|C0021149|C0013595|C0027627|C1274040
"Hemoglobin, albumin (Alb), electrolytes, blood urea nitrogen (BUN) and clinical complications were documented.","Hemoglobin, albumin (Alb), electrolytes, blood urea nitrogen (BUN) clinical complications documented.",C0019046|C0001924|G0000000|C0013832|C0005767|C0041942|C0028158|G0000000|C0205210|C0009566|C1301725
"Secondary outcomes included: Fugl-Meyer Assessment (FMA) for motor function, bedside swallowing assessment (BSA) and videofluoroscopic swallowing study (VFSS) for swallowing function, the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) for cognitive function, and the adverse reaction of acupuncture for safety assessment.","Secondary outcomes included: Fugl-Meyer Assessment (FMA) motor function, bedside swallowing assessment (BSA) videofluoroscopic swallowing study (VFSS) swallowing function, Mini-Mental State Examination (MMSE) Montreal Cognitive Assessment (MoCA) cognitive function, adverse reaction acupuncture safety assessment.",C0027627|C1274040|C0332257|G0000000|C1261322|C2332774|C1513492|C0031843|G0000000|C0011167|C1261322|G0000000|C1660599|C0011167|C0557651|G0000000|C0011167|C0031843|C0445542|C1301808|G0000000|C0451306|G0000000|C1516691|C1261322|C3541265|C1516691|C0031843|G0000000|C0443286|C0001299|C0036043|C1261322
"The primary efficacy end point was a comparison of the proportion of patients in each group achieving an erythropoietic response, which was defined as Hb increment of ≥ 2.0 g/dL from baseline or achievement of Hb ≥12 g/dL in the absence of transfusions during the preceding 28 days.","The primary efficacy comparison proportion patients achieving erythropoietic response, defined Hb increment ≥ 2.0 g/dL baseline achievement Hb ≥12 g/dL absence transfusions preceding 28 days.",G0000000|C0205225|C1280519|C1707455|C1709707|C0030705|G0000000|C0312829|C0871261|C1704788|C0019046|C1705117|G0000000|G0000000|C0439267|C0168634|C0001072|C0019046|G0000000|C0439267|C0332197|C0005841|C0332152|C0450371|C0439228
"Four secondary endpoints are included in this report: sensitivity, specificity, additional-imaging-recommendation-rate (i.e.call-back plus recommendation for short-term follow-up), and positive predictive value of biopsy (PPV).","Four secondary endpoints included report: sensitivity, specificity, additional-imaging-recommendation-rate (i.e.call-back recommendation short-term follow-up), positive predictive biopsy (PPV).",C0205450|C0027627|C2349179|C0332257|C0684224|C0020517|C0037791|C1524062|C0683454|C0034866|C0443303|C0589120|C0439178|C0681890|C0005558|C1514243
"We found no substantial effect of anthelminthic treatment during pregnancy on the child's response to immunogens, on infectious disease incidence, or on anaemia, growth, motor or cognitive development, to age 5 years.","We substantial anthelminthic treatment pregnancy child's response immunogens, infectious disease incidence, anaemia, growth, motor cognitive development, age 5 years.",G0000000|G0000000|C0003158|C0039798|C0032961|C0008059|C0871261|C0003320|C0009450|C0012634|C0021149|C0002871|C0018270|C1513492|C1516691|C0243107|C0001779|G0000000|C0439234
"The primary endpoint was mortality from breast cancers (with breast cancer coded as the underlying cause of death) diagnosed during the intervention period, before the participant's first NHSBSP screen.","The primary endpoint mortality breast cancers (with breast cancer coded underlying death) diagnosed intervention period, participant's NHSBSP screen.",G0000000|C0205225|C2349179|C0026565|C0006141|C0006826|G0000000|C0006141|C0006826|C0009219|G0000000|C0011065|C0011900|C0886296|C0439531|C0679646|G0000000|C0220908
This showed no statistical difference in risk of recurrence between the abagovomab-treated and placebo groups.,This statistical difference risk recurrence abagovomab-treated placebo groups.,G0000000|C0038215|C1705241|C0035647|C0034897|C1832044|C0032042|C0441833
